Protagonist Therapeutics Inc. (NASDAQ:PTGX) does about 430.22K shares in volume on a normal day but saw 1076137 shares change hands in Friday trading. The company now has a market cap of 642.35M USD and an enterprise value of about $440.24M. Its current market price is $15.69, marking a decrease of -10.09% compared to the previous close of $17.45. The 52 week high reached by this stock is $19.67 whilst the lowest price level in 52 weeks is $4.47. The script in recent trading has seen the stock touch a high of $17.41 and a low of $14.16.

Protagonist Therapeutics Inc. (PTGX) has a 20-day trading average at $16.55 and the current price is -20.23% off the 52-week high compared with 251.01% distance from its 52-week low. The 50-day simple moving average of the closing price is $16.82 and its 200-day simple moving average is $10.88. If we look at the stock’s price movements over the week, volatility stands at 8.57%, which decreases to 6.39% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 44.52 to suggest the stock is neutral.

4 analysts observing the Protagonist Therapeutics Inc. (PTGX) stock have set the 12-month price targets for the company’s shares at between $27.00 and $37.00. The median price target is 45.9% away from the current levels at $29.00.

FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 15, 2020 when Jefferies initiated the stock to “Buy” and issued a price target of $27. H.C. Wainwright initiated its price target at $23.

The current price level is -5.45%, -6.78%, and 44.36% away from its SMA20, SMA50, and SMA200 respectively, with the PTGX price moving above the 50-day SMA on August 14. Protagonist Therapeutics Inc. (PTGX) stock is down -12.64% over the week and -4.15% over the past month. Its price is 122.55% year-to-date and 57.06% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.61 below consensus estimates by -$0.02. The company’s next earnings report is expected on 11/10/2020, with forecasts estimating quarterly EPS at -$0.61 and -$2.54 for whole year. PTGX’s earnings per share are forecast to grow by 14.80% this year and 11.40% over next year. Expected sales for next quarter are $2.2 million, which analysts say will come at $14.24 million for the current fiscal year and next year at $20 million. In addition, estimates put the company’s current quarterly revenue at an average of $2.15 million.

Its 12-month price target is $29.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $27.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $37.00.

Outstanding shares total 32.80M with insiders holding 3.16% of the shares and institutional holders owning 90.01% of the company’s common stock. The company has a return on investment of -88.90% and return on equity of -72.40%. The beta has a value of 1.29. Price to book ratio is 3.07 and price to sales ratio is 38.46.

According to a U.S. Securities and Exchange Commission filing, Fidelity Series Small Cap Opportu has added its position in Protagonist Therapeutics Inc. (PTGX) to 1,324,329 shares, mirroring a recent increase by 1.51%. Fidelity Series Small Cap Opportu added 19638.0 shares of Protagonist Therapeutics Inc. common stock bringing its total worth to about $20.83 million at the end of recent close, SEC documents show. Fidelity Series Small Cap Opportu isn’t the only investment manager who changed stakes and is followed by Fidelity Growth Company Fund, which sold off 2537.0 shares to end up with 958,926 shares worth $15.08 million. Vanguard Total Stock Market Index cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 2.32% position in Protagonist Therapeutics Inc. thanks to 0.8 million shares amounting to $12.54 million.